The model
The CSC is the enabler. Control is the goal. The LSA monetizes it.
In a direct supply model, a health system trades directly with its manufacturers through a consolidated service center it owns or controls. Supply from every source is merged, stored and delivered from that center, and Logistics Service Agreements turn the discipline it creates into money. These are the benefits, in the order that matters.
01 · Value
The health system captures savings that were sitting in the manufacturer's cost-to-serve.
This is the benefit that pays for the model. A manufacturer serving hospitals through the conventional channel pays for GPO administrative fees, distributor chargebacks and cost-plus fees, sales tracing, and the selling effort needed to hold share on multi-source contracts. A CSC that buys in bulk to one ship-to point, on a fixed schedule, with electronic payment and clean data, removes much of that cost. The Logistics Service Agreement returns a share of it to the health system, as direct funding or as lower net price.
Our LSA programs draw on five funding sources:
- Channel fees: the market-share acquisition and retention costs the manufacturer no longer has to spend.
- Supply chain efficiencies: lower order-to-cash cost from consolidated, scheduled, electronic ordering.
- Sales tracing: the sales data the manufacturer needs, returned by the CSC instead of bought from a distributor.
- Prompt and electronic payment.
- Service fees and penalties: charges for the inefficiency a manufacturer's own practices create.
What each source is worth varies widely. It depends on what the CSC can actually do, how strongly the health system governs it, and whether its culture holds the discipline the manufacturer is paying for. Our assessment examines all three and sets the ranges for that health system's model, rather than borrowing someone else's. Either way, the money comes from the manufacturer relationship, not from the storeroom.
02 · Commitment pricing
Commitment, not size, earns the best price.
A GPO contract buys access pricing: a price any member can reach, on a contract that usually names several competing manufacturers. A health system with its own CSC can do what a GPO cannot. It can commit a defined share of its volume to one manufacturer, for a longer term, and deliver that commitment through a single standardized formulary. That commitment lowers the manufacturer's cost of winning and keeping the business, and the price follows. The GPO moves to a support role, rather than being the place where the price is set.
03 · Control
The health system owns its supply, its demand signal and its data.
In the conventional model the distributor sees the health system's total spend, and that visibility is worth more to the distributor than the distribution margin. Distribution now earns at or near break-even for the companies that do it. It is the price of seeing a customer's spend, and of the chance to convert it to the distributor's own products.
A CSC takes that position back. The health system holds the stock, sees consumption at the point of use, plans demand on its own data, and decides what is standardized, substituted or moved to private label under its own brand. The distributor becomes secondary: it carries the long tail of smaller manufacturers not under an LSA, in case quantities, to the CSC only, and never to a hospital.
04 · Risk
Supply sovereignty: a direct trader moves up the allocation list.
When supply is short, manufacturers allocate. A health system trading directly, under committed agreements, is a preferred customer in that allocation, ahead of intermediaries with some manufacturers. Its safety stock sits in one place it controls, not spread across storerooms or held by a third party for many customers at once.
Shortages are not going away. Disruption to oil flows reaches plastics and drug inputs, and the long-term global problems behind recent shortages remain unresolved. The mantra for the next generation of supply chain executives is supply chain sovereignty and control, with that control monetized.
05 · Operations
Inside the hospital, the savings are real but slower, and they are not the case.
A distribution operation run as a distribution business outperforms a hospital storeroom. A conventional CSC picks at 100 or more lines per hour per person against about 50 in a hospital storeroom, and an automated CSC picks upwards of 400. Consolidated, scheduled deliveries replace daily direct shipments from dozens of vendors. Storeroom space returns to clinical use, and two-bin kanban replenishment at the point of use takes supply tasks away from nurses.
Inventory falls by 20 to 30%, but over several years, and only as fast as clinical staff release stock to a CSC that has earned their trust. Perioperative inventory, the most expensive in the building, is the last to move. Labor displaced at receiving docks is usually reassigned to the operating room's inventory, not removed from the payroll. Count these savings, but as complementary benefits. A business case that rests on them is pointed in the wrong direction.
06 · Integration and growth
Built agnostic, the CSC serves every customer the health system will ever have.
A CSC on its own operating technologies, independent of the ERP and connected by EDI, sells to its customers rather than transferring stock to them. That design serves owned hospitals, acquisitions, managed and affiliated facilities, non-acute sites and 340B entities from day one, without re-platforming when the system grows.
The same building becomes the platform for the next services: pharmacy distribution and central fill, custom packs and sterile processing, clinical engineering, an IT depot. Each is evaluated at the start, sized for in the building, and added one at a time with its own business case once the core distribution operation is stable.
07 · Why manufacturers pay
If the manufacturer does not win, the funding stops.
The model is not a squeeze. The manufacturer ships in bulk to one location on a predictable cadence, is paid electronically and on time, receives the sales data it would otherwise buy, and keeps a concentrated, long-term share of the business without paying to defend it on every contract cycle. Its SG&A comes down. The health system's cost to acquire comes down. The parties that lose are the intermediaries whose value was always the question.
That is why the commercial terms are negotiated hard and the operating relationship afterward is collaborative. Both are necessary.
The condition
None of this arrives on its own.
Every benefit above depends on three things: LSAs executed before standardization, a CSC built and run as an arm's-length distribution business, and supply chain and clinical governance strong enough to hold the design through leadership change. Most CSCs that under-deliver have the building and not the rest. Testing for the rest is the first thing our assessment does.
Contact
If you are about to commit capital to a CSC, or the one you built is not producing what it promised, talk to us before the next decision.
James Grieger answers this address and this phone himself.